Filing Details
- Accession Number:
- 0001103021-19-000050
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-04 16:17:26
- Reporting Period:
- 2019-12-02
- Accepted Time:
- 2019-12-04 16:17:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1103021 | Biodelivery Sciences International Inc | BDSI | Pharmaceutical Preparations (2834) | 352089858 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1739458 | Herm Cukier | C/O Biodelivery Sciences Intl, Inc. 4131 Parklake Ave. Suite 225 Raleigh NC 27612 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-12-02 | 38,461 | $2.18 | 74,842 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-12-02 | 38,461 | $6.82 | 36,381 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (right to buy) | Disposition | 2019-12-02 | 38,461 | $0.00 | 38,461 | $2.18 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
761,539 | 2019-05-08 | 2028-06-04 | No | 4 | M | Direct |
Footnotes
- On December 2, 2019, the Reporting Person sold an aggregate of 38,461 shares of the Issuer's Common Stock at a weighted average price of $6.82 per share. The highest sale price for the Common Stock was $6.85 per share and the lowest sale price was $6.81 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
- The option representing a right to purchase a total of 800,000 shares, became exercisable in three equal installments beginning May 8, 2019.